Raynaud phenomenon in three patients with acquired immune deficiency syndrome-related Kaposi sarcoma treated with bleomycin.
The authors report three cases of Raynaud phenomenon that developed during doxorubicin, bleomycin, and vincristine (ABV) therapy for acquired immune deficiency syndrome (AIDS)-related Kaposi sarcoma. Although Raynaud phenomenon is well documented as a side effect of bleomycin, vinblastine, and cisplatin chemotherapy for germ cell neoplasms, it has not been widely documented in patients with AIDS.
von Gunten
C F
CF
Northwestern University, Chicago, Illinois 60611.
Roth
E L
EL
Von Roenn
J H
JH
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D006679:HIV Seropositivity / Q000150:complications; D006801:Humans; D008297:Male; D011928:Raynaud Disease / Q000139:chemically induced*; D012514:Sarcoma, Kaposi / Q000150:complications* / Q000188:drug therapy; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects
D001761:Bleomycin; D014747:Vinblastine; D004317:Doxorubicin